nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABCG2—Nelfinavir—acquired immunodeficiency syndrome	0.0813	0.139	CbGbCtD
Afatinib—ABCG2—Saquinavir—acquired immunodeficiency syndrome	0.0735	0.126	CbGbCtD
Afatinib—ABCG2—Ritonavir—acquired immunodeficiency syndrome	0.0735	0.126	CbGbCtD
Afatinib—ABCG2—Zidovudine—acquired immunodeficiency syndrome	0.0705	0.121	CbGbCtD
Afatinib—ABCG2—Lamivudine—acquired immunodeficiency syndrome	0.0545	0.0933	CbGbCtD
Afatinib—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0387	0.0662	CbGbCtD
Afatinib—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.035	0.0598	CbGbCtD
Afatinib—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0302	0.0516	CbGbCtD
Afatinib—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0293	0.0501	CbGbCtD
Afatinib—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0265	0.0453	CbGbCtD
Afatinib—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0265	0.0453	CbGbCtD
Afatinib—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0254	0.0435	CbGbCtD
Afatinib—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.0197	0.0336	CbGbCtD
Afatinib—BLK—lymphoid tissue—acquired immunodeficiency syndrome	0.00314	0.0339	CbGeAlD
Afatinib—BLK—blood—acquired immunodeficiency syndrome	0.00296	0.0319	CbGeAlD
Afatinib—ERBB2—skin of body—acquired immunodeficiency syndrome	0.00266	0.0287	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—acquired immunodeficiency syndrome	0.00215	0.0232	CbGeAlD
Afatinib—ERBB2—digestive system—acquired immunodeficiency syndrome	0.00213	0.023	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00207	0.0224	CbGeAlD
Afatinib—ERBB2—blood—acquired immunodeficiency syndrome	0.00203	0.0219	CbGeAlD
Afatinib—PHKG2—lung—acquired immunodeficiency syndrome	0.00198	0.0213	CbGeAlD
Afatinib—ERBB4—spinal cord—acquired immunodeficiency syndrome	0.00195	0.0211	CbGeAlD
Afatinib—EPHA6—nervous system—acquired immunodeficiency syndrome	0.0019	0.0205	CbGeAlD
Afatinib—ERBB4—vagina—acquired immunodeficiency syndrome	0.00188	0.0203	CbGeAlD
Afatinib—HIPK4—brain—acquired immunodeficiency syndrome	0.00183	0.0198	CbGeAlD
Afatinib—PHKG2—nervous system—acquired immunodeficiency syndrome	0.00183	0.0197	CbGeAlD
Afatinib—EPHA6—central nervous system—acquired immunodeficiency syndrome	0.00183	0.0197	CbGeAlD
Afatinib—ERBB2—lung—acquired immunodeficiency syndrome	0.00178	0.0192	CbGeAlD
Afatinib—ERBB4—lung—acquired immunodeficiency syndrome	0.00178	0.0192	CbGeAlD
Afatinib—BLK—lymph node—acquired immunodeficiency syndrome	0.00177	0.0191	CbGeAlD
Afatinib—PHKG2—central nervous system—acquired immunodeficiency syndrome	0.00176	0.019	CbGeAlD
Afatinib—DYRK1A—lung—acquired immunodeficiency syndrome	0.00171	0.0185	CbGeAlD
Afatinib—ERBB2—nervous system—acquired immunodeficiency syndrome	0.00164	0.0178	CbGeAlD
Afatinib—ERBB4—nervous system—acquired immunodeficiency syndrome	0.00164	0.0178	CbGeAlD
Afatinib—ERBB2—central nervous system—acquired immunodeficiency syndrome	0.00158	0.0171	CbGeAlD
Afatinib—ERBB4—central nervous system—acquired immunodeficiency syndrome	0.00158	0.0171	CbGeAlD
Afatinib—DYRK1A—nervous system—acquired immunodeficiency syndrome	0.00158	0.0171	CbGeAlD
Afatinib—DYRK1A—central nervous system—acquired immunodeficiency syndrome	0.00152	0.0165	CbGeAlD
Afatinib—IRAK1—blood—acquired immunodeficiency syndrome	0.00152	0.0164	CbGeAlD
Afatinib—EGFR—lung—acquired immunodeficiency syndrome	0.00151	0.0163	CbGeAlD
Afatinib—LCK—blood—acquired immunodeficiency syndrome	0.00148	0.016	CbGeAlD
Afatinib—IRAK1—bone marrow—acquired immunodeficiency syndrome	0.00147	0.0158	CbGeAlD
Afatinib—EPHA6—brain—acquired immunodeficiency syndrome	0.00145	0.0156	CbGeAlD
Afatinib—LCK—bone marrow—acquired immunodeficiency syndrome	0.00143	0.0154	CbGeAlD
Afatinib—PHKG2—brain—acquired immunodeficiency syndrome	0.0014	0.0151	CbGeAlD
Afatinib—LCK—vagina—acquired immunodeficiency syndrome	0.00137	0.0148	CbGeAlD
Afatinib—PHKG2—lymph node—acquired immunodeficiency syndrome	0.00135	0.0146	CbGeAlD
Afatinib—IRAK1—lung—acquired immunodeficiency syndrome	0.00133	0.0143	CbGeAlD
Afatinib—LCK—lung—acquired immunodeficiency syndrome	0.0013	0.014	CbGeAlD
Afatinib—ABL1—retina—acquired immunodeficiency syndrome	0.00127	0.0137	CbGeAlD
Afatinib—ERBB4—brain—acquired immunodeficiency syndrome	0.00126	0.0136	CbGeAlD
Afatinib—ERBB2—brain—acquired immunodeficiency syndrome	0.00126	0.0136	CbGeAlD
Afatinib—ERBB2—lymph node—acquired immunodeficiency syndrome	0.00121	0.0131	CbGeAlD
Afatinib—DYRK1A—brain—acquired immunodeficiency syndrome	0.00121	0.0131	CbGeAlD
Afatinib—DYRK1A—lymph node—acquired immunodeficiency syndrome	0.00117	0.0126	CbGeAlD
Afatinib—ABL1—skin of body—acquired immunodeficiency syndrome	0.00111	0.012	CbGeAlD
Afatinib—EGFR—brain—acquired immunodeficiency syndrome	0.00107	0.0115	CbGeAlD
Afatinib—EGFR—lymph node—acquired immunodeficiency syndrome	0.00103	0.0111	CbGeAlD
Afatinib—IRAK1—brain—acquired immunodeficiency syndrome	0.00094	0.0101	CbGeAlD
Afatinib—IRAK1—lymph node—acquired immunodeficiency syndrome	0.000909	0.00981	CbGeAlD
Afatinib—ABL1—lymphoid tissue—acquired immunodeficiency syndrome	0.000902	0.00974	CbGeAlD
Afatinib—ABL1—digestive system—acquired immunodeficiency syndrome	0.000891	0.00962	CbGeAlD
Afatinib—LCK—lymph node—acquired immunodeficiency syndrome	0.000886	0.00956	CbGeAlD
Afatinib—ABL1—blood—acquired immunodeficiency syndrome	0.000849	0.00916	CbGeAlD
Afatinib—ABL1—bone marrow—acquired immunodeficiency syndrome	0.000821	0.00887	CbGeAlD
Afatinib—ABL1—spinal cord—acquired immunodeficiency syndrome	0.000818	0.00883	CbGeAlD
Afatinib—ABL1—vagina—acquired immunodeficiency syndrome	0.000787	0.00849	CbGeAlD
Afatinib—ABL1—lung—acquired immunodeficiency syndrome	0.000744	0.00803	CbGeAlD
Afatinib—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000721	0.00778	CbGeAlD
Afatinib—ABL1—nervous system—acquired immunodeficiency syndrome	0.000689	0.00744	CbGeAlD
Afatinib—ABL1—central nervous system—acquired immunodeficiency syndrome	0.000663	0.00716	CbGeAlD
Afatinib—Vandetanib—ALB—acquired immunodeficiency syndrome	0.00065	0.513	CrCbGaD
Afatinib—Gefitinib—ALB—acquired immunodeficiency syndrome	0.000617	0.487	CrCbGaD
Afatinib—ABCG2—blood—acquired immunodeficiency syndrome	0.000535	0.00578	CbGeAlD
Afatinib—ABL1—brain—acquired immunodeficiency syndrome	0.000527	0.00569	CbGeAlD
Afatinib—ABCG2—bone marrow—acquired immunodeficiency syndrome	0.000518	0.00559	CbGeAlD
Afatinib—ABCG2—spinal cord—acquired immunodeficiency syndrome	0.000516	0.00557	CbGeAlD
Afatinib—ABL1—lymph node—acquired immunodeficiency syndrome	0.000509	0.00549	CbGeAlD
Afatinib—ABCG2—vagina—acquired immunodeficiency syndrome	0.000496	0.00536	CbGeAlD
Afatinib—ABCG2—lung—acquired immunodeficiency syndrome	0.000469	0.00507	CbGeAlD
Afatinib—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000425	0.00183	CcSEcCtD
Afatinib—Back pain—Efavirenz—acquired immunodeficiency syndrome	0.000424	0.00182	CcSEcCtD
Afatinib—Insomnia—Stavudine—acquired immunodeficiency syndrome	0.000424	0.00182	CcSEcCtD
Afatinib—Urinary tract disorder—Saquinavir—acquired immunodeficiency syndrome	0.000423	0.00182	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000422	0.00181	CcSEcCtD
Afatinib—Decreased appetite—Nevirapine—acquired immunodeficiency syndrome	0.000422	0.00181	CcSEcCtD
Afatinib—Connective tissue disorder—Saquinavir—acquired immunodeficiency syndrome	0.000421	0.00181	CcSEcCtD
Afatinib—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.00042	0.00181	CcSEcCtD
Afatinib—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000419	0.0018	CcSEcCtD
Afatinib—Dyspnoea—Nelfinavir—acquired immunodeficiency syndrome	0.000419	0.0018	CcSEcCtD
Afatinib—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000419	0.0018	CcSEcCtD
Afatinib—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000419	0.0018	CcSEcCtD
Afatinib—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000418	0.0018	CcSEcCtD
Afatinib—Insomnia—Abacavir—acquired immunodeficiency syndrome	0.000417	0.0018	CcSEcCtD
Afatinib—Eye disorder—Ritonavir—acquired immunodeficiency syndrome	0.000416	0.00179	CcSEcCtD
Afatinib—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.000413	0.00178	CcSEcCtD
Afatinib—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000412	0.00177	CcSEcCtD
Afatinib—Dyspnoea—Abacavir—acquired immunodeficiency syndrome	0.000411	0.00177	CcSEcCtD
Afatinib—Dysgeusia—Delavirdine—acquired immunodeficiency syndrome	0.000411	0.00177	CcSEcCtD
Afatinib—Decreased appetite—Nelfinavir—acquired immunodeficiency syndrome	0.000408	0.00176	CcSEcCtD
Afatinib—Decreased appetite—Stavudine—acquired immunodeficiency syndrome	0.000407	0.00175	CcSEcCtD
Afatinib—Back pain—Delavirdine—acquired immunodeficiency syndrome	0.000406	0.00175	CcSEcCtD
Afatinib—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000406	0.00175	CcSEcCtD
Afatinib—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000405	0.00174	CcSEcCtD
Afatinib—Cough—Indinavir—acquired immunodeficiency syndrome	0.000405	0.00174	CcSEcCtD
Afatinib—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000404	0.00174	CcSEcCtD
Afatinib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000404	0.00174	CcSEcCtD
Afatinib—Muscle spasms—Delavirdine—acquired immunodeficiency syndrome	0.000403	0.00173	CcSEcCtD
Afatinib—Connective tissue disorder—Lamivudine—acquired immunodeficiency syndrome	0.000402	0.00173	CcSEcCtD
Afatinib—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000401	0.00173	CcSEcCtD
Afatinib—Decreased appetite—Abacavir—acquired immunodeficiency syndrome	0.000401	0.00173	CcSEcCtD
Afatinib—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.000401	0.00172	CcSEcCtD
Afatinib—Constipation—Stavudine—acquired immunodeficiency syndrome	0.0004	0.00172	CcSEcCtD
Afatinib—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000399	0.00172	CcSEcCtD
Afatinib—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000398	0.00171	CcSEcCtD
Afatinib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000398	0.00171	CcSEcCtD
Afatinib—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000395	0.0017	CcSEcCtD
Afatinib—ABCB1—retina—acquired immunodeficiency syndrome	0.000395	0.00426	CbGeAlD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000392	0.00169	CcSEcCtD
Afatinib—Mental disorder—Ritonavir—acquired immunodeficiency syndrome	0.00039	0.00168	CcSEcCtD
Afatinib—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000388	0.00167	CcSEcCtD
Afatinib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000387	0.00167	CcSEcCtD
Afatinib—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000386	0.00166	CcSEcCtD
Afatinib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000383	0.00165	CcSEcCtD
Afatinib—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000382	0.00165	CcSEcCtD
Afatinib—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000382	0.00164	CcSEcCtD
Afatinib—Dysgeusia—Ritonavir—acquired immunodeficiency syndrome	0.00038	0.00163	CcSEcCtD
Afatinib—Alopecia—Saquinavir—acquired immunodeficiency syndrome	0.000379	0.00163	CcSEcCtD
Afatinib—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000376	0.00162	CcSEcCtD
Afatinib—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000376	0.00162	CcSEcCtD
Afatinib—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000375	0.00161	CcSEcCtD
Afatinib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000373	0.00161	CcSEcCtD
Afatinib—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000373	0.00161	CcSEcCtD
Afatinib—Muscle spasms—Ritonavir—acquired immunodeficiency syndrome	0.000373	0.0016	CcSEcCtD
Afatinib—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000373	0.0016	CcSEcCtD
Afatinib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000371	0.0016	CcSEcCtD
Afatinib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000371	0.0016	CcSEcCtD
Afatinib—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000371	0.0016	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000371	0.00159	CcSEcCtD
Afatinib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.00037	0.00159	CcSEcCtD
Afatinib—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000369	0.00159	CcSEcCtD
Afatinib—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000369	0.00159	CcSEcCtD
Afatinib—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000368	0.00158	CcSEcCtD
Afatinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000368	0.00158	CcSEcCtD
Afatinib—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000366	0.00157	CcSEcCtD
Afatinib—Dysgeusia—Saquinavir—acquired immunodeficiency syndrome	0.000365	0.00157	CcSEcCtD
Afatinib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000365	0.00157	CcSEcCtD
Afatinib—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000363	0.00156	CcSEcCtD
Afatinib—Alopecia—Lamivudine—acquired immunodeficiency syndrome	0.000361	0.00156	CcSEcCtD
Afatinib—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000361	0.00155	CcSEcCtD
Afatinib—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000359	0.00154	CcSEcCtD
Afatinib—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000358	0.00154	CcSEcCtD
Afatinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000356	0.00153	CcSEcCtD
Afatinib—Decreased appetite—Zidovudine—acquired immunodeficiency syndrome	0.000354	0.00152	CcSEcCtD
Afatinib—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000351	0.00151	CcSEcCtD
Afatinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00151	CcSEcCtD
Afatinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00151	CcSEcCtD
Afatinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000351	0.00151	CcSEcCtD
Afatinib—Dysgeusia—Lamivudine—acquired immunodeficiency syndrome	0.000349	0.0015	CcSEcCtD
Afatinib—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000348	0.0015	CcSEcCtD
Afatinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000348	0.0015	CcSEcCtD
Afatinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000347	0.0015	CcSEcCtD
Afatinib—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000344	0.00148	CcSEcCtD
Afatinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000343	0.00148	CcSEcCtD
Afatinib—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000343	0.00148	CcSEcCtD
Afatinib—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000342	0.00147	CcSEcCtD
Afatinib—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000342	0.00147	CcSEcCtD
Afatinib—Rash—Didanosine—acquired immunodeficiency syndrome	0.00034	0.00146	CcSEcCtD
Afatinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.00034	0.00146	CcSEcCtD
Afatinib—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.00034	0.00146	CcSEcCtD
Afatinib—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.00146	CcSEcCtD
Afatinib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000338	0.00145	CcSEcCtD
Afatinib—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000337	0.00145	CcSEcCtD
Afatinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000337	0.00145	CcSEcCtD
Afatinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000336	0.00145	CcSEcCtD
Afatinib—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000333	0.00143	CcSEcCtD
Afatinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000332	0.00143	CcSEcCtD
Afatinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000332	0.00143	CcSEcCtD
Afatinib—ABCG2—brain—acquired immunodeficiency syndrome	0.000332	0.00359	CbGeAlD
Afatinib—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000332	0.00143	CcSEcCtD
Afatinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000331	0.00143	CcSEcCtD
Afatinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000331	0.00142	CcSEcCtD
Afatinib—Decreased appetite—Indinavir—acquired immunodeficiency syndrome	0.000329	0.00142	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000328	0.00141	CcSEcCtD
Afatinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000327	0.00141	CcSEcCtD
Afatinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000326	0.0014	CcSEcCtD
Afatinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000326	0.0014	CcSEcCtD
Afatinib—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000326	0.0014	CcSEcCtD
Afatinib—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000324	0.00139	CcSEcCtD
Afatinib—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000323	0.00139	CcSEcCtD
Afatinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000322	0.00138	CcSEcCtD
Afatinib—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000321	0.00138	CcSEcCtD
Afatinib—ABCG2—lymph node—acquired immunodeficiency syndrome	0.000321	0.00346	CbGeAlD
Afatinib—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00032	0.00138	CcSEcCtD
Afatinib—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00032	0.00138	CcSEcCtD
Afatinib—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000319	0.00137	CcSEcCtD
Afatinib—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000316	0.00136	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000316	0.00136	CcSEcCtD
Afatinib—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000315	0.00135	CcSEcCtD
Afatinib—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	0.000311	0.00134	CcSEcCtD
Afatinib—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.00134	CcSEcCtD
Afatinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000311	0.00134	CcSEcCtD
Afatinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.00134	CcSEcCtD
Afatinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.00031	0.00133	CcSEcCtD
Afatinib—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.00031	0.00133	CcSEcCtD
Afatinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000309	0.00133	CcSEcCtD
Afatinib—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000308	0.00133	CcSEcCtD
Afatinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00133	CcSEcCtD
Afatinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.00132	CcSEcCtD
Afatinib—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000306	0.00132	CcSEcCtD
Afatinib—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000306	0.00132	CcSEcCtD
Afatinib—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000306	0.00131	CcSEcCtD
Afatinib—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000305	0.00131	CcSEcCtD
Afatinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000305	0.00131	CcSEcCtD
Afatinib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000304	0.00131	CcSEcCtD
Afatinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000303	0.0013	CcSEcCtD
Afatinib—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.000301	0.0013	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000301	0.0013	CcSEcCtD
Afatinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000299	0.00129	CcSEcCtD
Afatinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000299	0.00129	CcSEcCtD
Afatinib—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000299	0.00129	CcSEcCtD
Afatinib—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000298	0.00128	CcSEcCtD
Afatinib—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	0.000297	0.00128	CcSEcCtD
Afatinib—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000296	0.00127	CcSEcCtD
Afatinib—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000296	0.00127	CcSEcCtD
Afatinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000296	0.00127	CcSEcCtD
Afatinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.00127	CcSEcCtD
Afatinib—Rash—Stavudine—acquired immunodeficiency syndrome	0.000295	0.00127	CcSEcCtD
Afatinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.00127	CcSEcCtD
Afatinib—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000295	0.00127	CcSEcCtD
Afatinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000294	0.00127	CcSEcCtD
Afatinib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000293	0.00126	CcSEcCtD
Afatinib—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000293	0.00126	CcSEcCtD
Afatinib—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000293	0.00126	CcSEcCtD
Afatinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000292	0.00126	CcSEcCtD
Afatinib—Rash—Abacavir—acquired immunodeficiency syndrome	0.000291	0.00125	CcSEcCtD
Afatinib—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000291	0.00125	CcSEcCtD
Afatinib—Headache—Abacavir—acquired immunodeficiency syndrome	0.000289	0.00124	CcSEcCtD
Afatinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.000289	0.00124	CcSEcCtD
Afatinib—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000288	0.00124	CcSEcCtD
Afatinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000288	0.00124	CcSEcCtD
Afatinib—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000286	0.00123	CcSEcCtD
Afatinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.00123	CcSEcCtD
Afatinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000283	0.00122	CcSEcCtD
Afatinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000282	0.00121	CcSEcCtD
Afatinib—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000282	0.00121	CcSEcCtD
Afatinib—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.00028	0.00303	CbGeAlD
Afatinib—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000279	0.0012	CcSEcCtD
Afatinib—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000279	0.0012	CcSEcCtD
Afatinib—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000278	0.0012	CcSEcCtD
Afatinib—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000278	0.0012	CcSEcCtD
Afatinib—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000277	0.00299	CbGeAlD
Afatinib—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.000275	0.00119	CcSEcCtD
Afatinib—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	0.000275	0.00118	CcSEcCtD
Afatinib—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000274	0.00118	CcSEcCtD
Afatinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00118	CcSEcCtD
Afatinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00117	CcSEcCtD
Afatinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000272	0.00117	CcSEcCtD
Afatinib—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.00117	CcSEcCtD
Afatinib—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000271	0.00116	CcSEcCtD
Afatinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000271	0.00116	CcSEcCtD
Afatinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000269	0.00116	CcSEcCtD
Afatinib—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000268	0.00115	CcSEcCtD
Afatinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000268	0.00115	CcSEcCtD
Afatinib—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	0.000265	0.00114	CcSEcCtD
Afatinib—ABCB1—blood—acquired immunodeficiency syndrome	0.000264	0.00285	CbGeAlD
Afatinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00113	CcSEcCtD
Afatinib—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000263	0.00113	CcSEcCtD
Afatinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00113	CcSEcCtD
Afatinib—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.00112	CcSEcCtD
Afatinib—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000259	0.00111	CcSEcCtD
Afatinib—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000259	0.00111	CcSEcCtD
Afatinib—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000259	0.00111	CcSEcCtD
Afatinib—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000257	0.0011	CcSEcCtD
Afatinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000257	0.0011	CcSEcCtD
Afatinib—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000256	0.0011	CcSEcCtD
Afatinib—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000256	0.0011	CcSEcCtD
Afatinib—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000255	0.00276	CbGeAlD
Afatinib—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000255	0.0011	CcSEcCtD
Afatinib—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000254	0.00274	CbGeAlD
Afatinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000253	0.00109	CcSEcCtD
Afatinib—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	0.000253	0.00109	CcSEcCtD
Afatinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00108	CcSEcCtD
Afatinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000251	0.00108	CcSEcCtD
Afatinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00025	0.00108	CcSEcCtD
Afatinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00025	0.00108	CcSEcCtD
Afatinib—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00107	CcSEcCtD
Afatinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000246	0.00106	CcSEcCtD
Afatinib—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000245	0.00105	CcSEcCtD
Afatinib—ABCB1—vagina—acquired immunodeficiency syndrome	0.000245	0.00264	CbGeAlD
Afatinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000242	0.00104	CcSEcCtD
Afatinib—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000242	0.00104	CcSEcCtD
Afatinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000241	0.00104	CcSEcCtD
Afatinib—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000241	0.00104	CcSEcCtD
Afatinib—Rash—Indinavir—acquired immunodeficiency syndrome	0.000239	0.00103	CcSEcCtD
Afatinib—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000238	0.00103	CcSEcCtD
Afatinib—Headache—Indinavir—acquired immunodeficiency syndrome	0.000237	0.00102	CcSEcCtD
Afatinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000237	0.00102	CcSEcCtD
Afatinib—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000234	0.00101	CcSEcCtD
Afatinib—ABCB1—lung—acquired immunodeficiency syndrome	0.000231	0.0025	CbGeAlD
Afatinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00023	0.000989	CcSEcCtD
Afatinib—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.000979	CcSEcCtD
Afatinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000227	0.000977	CcSEcCtD
Afatinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.000974	CcSEcCtD
Afatinib—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000226	0.00097	CcSEcCtD
Afatinib—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000225	0.00097	CcSEcCtD
Afatinib—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000225	0.000968	CcSEcCtD
Afatinib—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000224	0.000964	CcSEcCtD
Afatinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000224	0.000964	CcSEcCtD
Afatinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000219	0.00094	CcSEcCtD
Afatinib—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000218	0.000936	CcSEcCtD
Afatinib—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.000932	CcSEcCtD
Afatinib—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000929	CcSEcCtD
Afatinib—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000928	CcSEcCtD
Afatinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.000927	CcSEcCtD
Afatinib—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.000923	CcSEcCtD
Afatinib—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000214	0.00231	CbGeAlD
Afatinib—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000212	0.000914	CcSEcCtD
Afatinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.000901	CcSEcCtD
Afatinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.000897	CcSEcCtD
Afatinib—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000897	CcSEcCtD
Afatinib—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000206	0.00223	CbGeAlD
Afatinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000206	0.000885	CcSEcCtD
Afatinib—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000203	0.000875	CcSEcCtD
Afatinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.000867	CcSEcCtD
Afatinib—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000866	CcSEcCtD
Afatinib—Rash—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000859	CcSEcCtD
Afatinib—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.000858	CcSEcCtD
Afatinib—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000199	0.000856	CcSEcCtD
Afatinib—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.000853	CcSEcCtD
Afatinib—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000194	0.000833	CcSEcCtD
Afatinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.000827	CcSEcCtD
Afatinib—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000826	CcSEcCtD
Afatinib—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000826	CcSEcCtD
Afatinib—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.000821	CcSEcCtD
Afatinib—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000188	0.000809	CcSEcCtD
Afatinib—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000185	0.000795	CcSEcCtD
Afatinib—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000788	CcSEcCtD
Afatinib—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000788	CcSEcCtD
Afatinib—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.000783	CcSEcCtD
Afatinib—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000181	0.000779	CcSEcCtD
Afatinib—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000173	0.000743	CcSEcCtD
Afatinib—ABCB1—brain—acquired immunodeficiency syndrome	0.000164	0.00177	CbGeAlD
Afatinib—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000158	0.00171	CbGeAlD
Afatinib—IRAK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.01e-05	0.000784	CbGpPWpGaD
Afatinib—PHKG2—Disease—CD4—acquired immunodeficiency syndrome	6.98e-05	0.000781	CbGpPWpGaD
Afatinib—EGFR—Immune System—ACTG1—acquired immunodeficiency syndrome	6.95e-05	0.000778	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	6.92e-05	0.000775	CbGpPWpGaD
Afatinib—LCK—Immune System—ACTG1—acquired immunodeficiency syndrome	6.7e-05	0.000749	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CCR2—acquired immunodeficiency syndrome	6.7e-05	0.000749	CbGpPWpGaD
Afatinib—ABL1—Immune System—MBL2—acquired immunodeficiency syndrome	6.68e-05	0.000748	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	6.67e-05	0.000746	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—ALB—acquired immunodeficiency syndrome	6.63e-05	0.000742	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.62e-05	0.000741	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD40LG—acquired immunodeficiency syndrome	6.6e-05	0.000738	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—TNF—acquired immunodeficiency syndrome	6.6e-05	0.000738	CbGpPWpGaD
Afatinib—LCK—HIV Infection—CD4—acquired immunodeficiency syndrome	6.58e-05	0.000736	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD8A—acquired immunodeficiency syndrome	6.53e-05	0.00073	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CSF2—acquired immunodeficiency syndrome	6.53e-05	0.00073	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	6.52e-05	0.00073	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD40LG—acquired immunodeficiency syndrome	6.5e-05	0.000727	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	6.45e-05	0.000722	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—CD4—acquired immunodeficiency syndrome	6.44e-05	0.00072	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CSF2—acquired immunodeficiency syndrome	6.43e-05	0.000719	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD8A—acquired immunodeficiency syndrome	6.43e-05	0.000719	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—CD4—acquired immunodeficiency syndrome	6.34e-05	0.000709	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HLA-B—acquired immunodeficiency syndrome	6.28e-05	0.000702	CbGpPWpGaD
Afatinib—BLK—Immune System—CD40LG—acquired immunodeficiency syndrome	6.25e-05	0.0007	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	6.22e-05	0.000696	CbGpPWpGaD
Afatinib—LCK—Signaling by Interleukins—IL6—acquired immunodeficiency syndrome	6.2e-05	0.000693	CbGpPWpGaD
Afatinib—BLK—Immune System—CSF2—acquired immunodeficiency syndrome	6.18e-05	0.000692	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HLA-B—acquired immunodeficiency syndrome	6.18e-05	0.000692	CbGpPWpGaD
Afatinib—BLK—Immune System—CD8A—acquired immunodeficiency syndrome	6.18e-05	0.000692	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	6.18e-05	0.000691	CbGpPWpGaD
Afatinib—ERBB2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	6.1e-05	0.000683	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	6.1e-05	0.000682	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	6.09e-05	0.000681	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNA1—acquired immunodeficiency syndrome	6.03e-05	0.000675	CbGpPWpGaD
Afatinib—ERBB4—Signaling by NGF—IL6—acquired immunodeficiency syndrome	6.01e-05	0.000673	CbGpPWpGaD
Afatinib—EGFR—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	5.99e-05	0.00067	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.99e-05	0.00067	CbGpPWpGaD
Afatinib—BLK—Immune System—HLA-B—acquired immunodeficiency syndrome	5.95e-05	0.000666	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	5.95e-05	0.000665	CbGpPWpGaD
Afatinib—ABL1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.91e-05	0.000661	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.9e-05	0.00066	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	5.86e-05	0.000655	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD79A—acquired immunodeficiency syndrome	5.85e-05	0.000655	CbGpPWpGaD
Afatinib—LCK—Hemostasis—CSF2—acquired immunodeficiency syndrome	5.8e-05	0.000649	CbGpPWpGaD
Afatinib—EGFR—Immune System—MBL2—acquired immunodeficiency syndrome	5.71e-05	0.000639	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.63e-05	0.00063	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.63e-05	0.00063	CbGpPWpGaD
Afatinib—EGFR—MAPK Signaling Pathway—TNF—acquired immunodeficiency syndrome	5.6e-05	0.000626	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.55e-05	0.000621	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.55e-05	0.000621	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IFNG—acquired immunodeficiency syndrome	5.54e-05	0.000619	CbGpPWpGaD
Afatinib—ERBB2—Axon guidance—IL6—acquired immunodeficiency syndrome	5.52e-05	0.000618	CbGpPWpGaD
Afatinib—ERBB2—Disease—CCR5—acquired immunodeficiency syndrome	5.51e-05	0.000617	CbGpPWpGaD
Afatinib—LCK—Immune System—MBL2—acquired immunodeficiency syndrome	5.5e-05	0.000616	CbGpPWpGaD
Afatinib—ERBB4—Disease—CCR5—acquired immunodeficiency syndrome	5.43e-05	0.000607	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.42e-05	0.000606	CbGpPWpGaD
Afatinib—EPHA6—Developmental Biology—IL6—acquired immunodeficiency syndrome	5.33e-05	0.000596	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.26e-05	0.000589	CbGpPWpGaD
Afatinib—ABL1—Immune System—CCR2—acquired immunodeficiency syndrome	5.24e-05	0.000586	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	5.21e-05	0.000583	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.2e-05	0.000582	CbGpPWpGaD
Afatinib—EGFR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	5.2e-05	0.000581	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	5.18e-05	0.00058	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	5.18e-05	0.00058	CbGpPWpGaD
Afatinib—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	5.17e-05	0.000578	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	5.07e-05	0.000567	CbGpPWpGaD
Afatinib—EGFR—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	5.05e-05	0.000565	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	5.02e-05	0.000562	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	5.01e-05	0.000561	CbGpPWpGaD
Afatinib—LCK—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	5.01e-05	0.00056	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	5e-05	0.00056	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.99e-05	0.000559	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.99e-05	0.000559	CbGpPWpGaD
Afatinib—EGFR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.97e-05	0.000556	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	4.92e-05	0.00055	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.9e-05	0.000548	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.89e-05	0.000547	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—acquired immunodeficiency syndrome	4.88e-05	0.000546	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	4.82e-05	0.00054	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.79e-05	0.000536	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.79e-05	0.000536	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD40LG—acquired immunodeficiency syndrome	4.77e-05	0.000534	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNA1—acquired immunodeficiency syndrome	4.72e-05	0.000528	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD8A—acquired immunodeficiency syndrome	4.72e-05	0.000528	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CSF2—acquired immunodeficiency syndrome	4.72e-05	0.000528	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.71e-05	0.000527	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.69e-05	0.000524	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	4.67e-05	0.000523	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—CD4—acquired immunodeficiency syndrome	4.65e-05	0.000521	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	4.65e-05	0.00052	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	4.63e-05	0.000518	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.61e-05	0.000516	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.61e-05	0.000516	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	4.6e-05	0.000515	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	4.6e-05	0.000515	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—ALB—acquired immunodeficiency syndrome	4.59e-05	0.000513	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD79A—acquired immunodeficiency syndrome	4.58e-05	0.000512	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HLA-B—acquired immunodeficiency syndrome	4.54e-05	0.000508	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.52e-05	0.000505	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	4.5e-05	0.000504	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	4.49e-05	0.000502	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	4.48e-05	0.000501	CbGpPWpGaD
Afatinib—EGFR—Immune System—CCR2—acquired immunodeficiency syndrome	4.48e-05	0.000501	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	4.46e-05	0.000499	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—IL6—acquired immunodeficiency syndrome	4.44e-05	0.000496	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	4.41e-05	0.000494	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	4.33e-05	0.000485	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	4.33e-05	0.000485	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	4.33e-05	0.000485	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.33e-05	0.000484	CbGpPWpGaD
Afatinib—LCK—Immune System—CCR2—acquired immunodeficiency syndrome	4.32e-05	0.000483	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	4.29e-05	0.00048	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.28e-05	0.000479	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	4.25e-05	0.000476	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	4.24e-05	0.000474	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.22e-05	0.000472	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.22e-05	0.000472	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	4.17e-05	0.000467	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—IL6—acquired immunodeficiency syndrome	4.17e-05	0.000467	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	4.17e-05	0.000467	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.16e-05	0.000465	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	4.14e-05	0.000463	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	4.1e-05	0.000459	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	4.08e-05	0.000457	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.07e-05	0.000455	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.07e-05	0.000455	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNA1—acquired immunodeficiency syndrome	4.03e-05	0.000451	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.94e-05	0.000441	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD79A—acquired immunodeficiency syndrome	3.91e-05	0.000438	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	3.91e-05	0.000438	CbGpPWpGaD
Afatinib—EGFR—Disease—CXCR4—acquired immunodeficiency syndrome	3.89e-05	0.000435	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNA1—acquired immunodeficiency syndrome	3.89e-05	0.000435	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IFNG—acquired immunodeficiency syndrome	3.88e-05	0.000434	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.86e-05	0.000432	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.84e-05	0.000429	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IFNG—acquired immunodeficiency syndrome	3.82e-05	0.000428	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.8e-05	0.000425	CbGpPWpGaD
Afatinib—LCK—Hemostasis—ALB—acquired immunodeficiency syndrome	3.78e-05	0.000423	CbGpPWpGaD
Afatinib—PHKG2—Disease—IL6—acquired immunodeficiency syndrome	3.78e-05	0.000422	CbGpPWpGaD
Afatinib—LCK—Immune System—CD79A—acquired immunodeficiency syndrome	3.77e-05	0.000422	CbGpPWpGaD
Afatinib—ERBB2—Immune System—CD4—acquired immunodeficiency syndrome	3.75e-05	0.000419	CbGpPWpGaD
Afatinib—LCK—Disease—CXCR4—acquired immunodeficiency syndrome	3.75e-05	0.000419	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD40LG—acquired immunodeficiency syndrome	3.73e-05	0.000418	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—IL2—acquired immunodeficiency syndrome	3.72e-05	0.000416	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.71e-05	0.000415	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.7e-05	0.000414	CbGpPWpGaD
Afatinib—ABL1—Immune System—CSF2—acquired immunodeficiency syndrome	3.69e-05	0.000413	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD8A—acquired immunodeficiency syndrome	3.69e-05	0.000413	CbGpPWpGaD
Afatinib—ERBB4—Immune System—CD4—acquired immunodeficiency syndrome	3.69e-05	0.000413	CbGpPWpGaD
Afatinib—BLK—Immune System—IFNG—acquired immunodeficiency syndrome	3.68e-05	0.000411	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.64e-05	0.000407	CbGpPWpGaD
Afatinib—ABL1—Immune System—HLA-B—acquired immunodeficiency syndrome	3.55e-05	0.000397	CbGpPWpGaD
Afatinib—BLK—Immune System—CD4—acquired immunodeficiency syndrome	3.55e-05	0.000397	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.51e-05	0.000392	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.48e-05	0.000389	CbGpPWpGaD
Afatinib—ERBB2—Disease—CD4—acquired immunodeficiency syndrome	3.46e-05	0.000387	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.45e-05	0.000386	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL2—acquired immunodeficiency syndrome	3.45e-05	0.000386	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.43e-05	0.000384	CbGpPWpGaD
Afatinib—ERBB4—Disease—CD4—acquired immunodeficiency syndrome	3.41e-05	0.000381	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL2—acquired immunodeficiency syndrome	3.4e-05	0.00038	CbGpPWpGaD
Afatinib—BLK—Immune System—IL2—acquired immunodeficiency syndrome	3.27e-05	0.000366	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.2e-05	0.000358	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD40LG—acquired immunodeficiency syndrome	3.19e-05	0.000357	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	3.17e-05	0.000355	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.16e-05	0.000353	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD8A—acquired immunodeficiency syndrome	3.16e-05	0.000353	CbGpPWpGaD
Afatinib—EGFR—Immune System—CSF2—acquired immunodeficiency syndrome	3.16e-05	0.000353	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—acquired immunodeficiency syndrome	3.12e-05	0.00035	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.11e-05	0.000348	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.1e-05	0.000347	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.09e-05	0.000345	CbGpPWpGaD
Afatinib—LCK—Immune System—CD40LG—acquired immunodeficiency syndrome	3.08e-05	0.000344	CbGpPWpGaD
Afatinib—LCK—Hemostasis—IL2—acquired immunodeficiency syndrome	3.06e-05	0.000343	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.05e-05	0.000341	CbGpPWpGaD
Afatinib—LCK—Immune System—CSF2—acquired immunodeficiency syndrome	3.04e-05	0.00034	CbGpPWpGaD
Afatinib—LCK—Immune System—CD8A—acquired immunodeficiency syndrome	3.04e-05	0.00034	CbGpPWpGaD
Afatinib—EGFR—Immune System—HLA-B—acquired immunodeficiency syndrome	3.04e-05	0.00034	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CD4—acquired immunodeficiency syndrome	3e-05	0.000335	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.99e-05	0.000334	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.95e-05	0.00033	CbGpPWpGaD
Afatinib—LCK—Immune System—HLA-B—acquired immunodeficiency syndrome	2.93e-05	0.000327	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.9e-05	0.000324	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.89e-05	0.000324	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	2.88e-05	0.000322	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.84e-05	0.000318	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IFNG—acquired immunodeficiency syndrome	2.81e-05	0.000314	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.79e-05	0.000312	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.79e-05	0.000312	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.76e-05	0.000309	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.72e-05	0.000305	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.72e-05	0.000305	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CD4—acquired immunodeficiency syndrome	2.71e-05	0.000303	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—acquired immunodeficiency syndrome	2.67e-05	0.000299	CbGpPWpGaD
Afatinib—EGFR—Disease—CCR5—acquired immunodeficiency syndrome	2.66e-05	0.000298	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.62e-05	0.000294	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.62e-05	0.000294	CbGpPWpGaD
Afatinib—LCK—Disease—CCR5—acquired immunodeficiency syndrome	2.57e-05	0.000287	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.55e-05	0.000285	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.52e-05	0.000282	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL2—acquired immunodeficiency syndrome	2.49e-05	0.000279	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.36e-05	0.000264	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.23e-05	0.000249	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.23e-05	0.000249	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.2e-05	0.000246	CbGpPWpGaD
Afatinib—ABL1—Immune System—IFNG—acquired immunodeficiency syndrome	2.2e-05	0.000246	CbGpPWpGaD
Afatinib—ABL1—Immune System—CD4—acquired immunodeficiency syndrome	2.12e-05	0.000237	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.07e-05	0.000232	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.04e-05	0.000228	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—acquired immunodeficiency syndrome	2.03e-05	0.000227	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—acquired immunodeficiency syndrome	2e-05	0.000223	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2e-05	0.000223	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.97e-05	0.00022	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.97e-05	0.00022	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL2—acquired immunodeficiency syndrome	1.95e-05	0.000218	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—acquired immunodeficiency syndrome	1.92e-05	0.000215	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.91e-05	0.000213	CbGpPWpGaD
Afatinib—EGFR—Immune System—IFNG—acquired immunodeficiency syndrome	1.88e-05	0.00021	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—acquired immunodeficiency syndrome	1.87e-05	0.000209	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.87e-05	0.000209	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—acquired immunodeficiency syndrome	1.84e-05	0.000206	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.83e-05	0.000204	CbGpPWpGaD
Afatinib—EGFR—Immune System—CD4—acquired immunodeficiency syndrome	1.81e-05	0.000203	CbGpPWpGaD
Afatinib—LCK—Immune System—IFNG—acquired immunodeficiency syndrome	1.81e-05	0.000202	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.8e-05	0.000201	CbGpPWpGaD
Afatinib—LCK—Immune System—CD4—acquired immunodeficiency syndrome	1.75e-05	0.000195	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.71e-05	0.000192	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.68e-05	0.000188	CbGpPWpGaD
Afatinib—EGFR—Disease—CD4—acquired immunodeficiency syndrome	1.67e-05	0.000187	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL2—acquired immunodeficiency syndrome	1.67e-05	0.000187	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.62e-05	0.000181	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—acquired immunodeficiency syndrome	1.61e-05	0.00018	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.61e-05	0.00018	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—acquired immunodeficiency syndrome	1.61e-05	0.00018	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—acquired immunodeficiency syndrome	1.48e-05	0.000166	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—acquired immunodeficiency syndrome	1.47e-05	0.000164	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000147	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.29e-05	0.000144	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—acquired immunodeficiency syndrome	1.15e-05	0.000128	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.08e-05	0.000121	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.07e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.04e-05	0.000116	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—acquired immunodeficiency syndrome	9.8e-06	0.00011	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.48e-06	0.000106	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—acquired immunodeficiency syndrome	9.45e-06	0.000106	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—acquired immunodeficiency syndrome	9.05e-06	0.000101	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—acquired immunodeficiency syndrome	8.72e-06	9.76e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	8.03e-06	8.98e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.34e-06	7.09e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.11e-06	6.83e-05	CbGpPWpGaD
